Etid klinik pou Melanom nan Tennessee
40 etid pou Melanom ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07751042A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478A Study of BI 3810944 in Patients With Advanced Cancer
- Tennessee Oncology, PLLC - Elliston Place Plaza DDU, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07224425Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07519655DESTINY-PANTUMOUR04
- Research Site, Nashville
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Tennessee Oncology - Chattanooga, Chattanooga
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06246916Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Baptist Cancer Center, Bartlett
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT05727904A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
Ap rekriteFaz 2
Jiska laj 25 · Tout sèks · Mizajou Sep 24, 2026 · NCT07621614Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Vanderbilt University/Ingram Cancer Center, Nashville
Ap rekriteFaz 3
Laj 75 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07068074Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Sep 18, 2026 · NCT06398418Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07287917A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04913285Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Saint Jude Children's Research Hospital, Memphis
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Project: Every Child for Younger Patients With Cancer
- T C Thompson Children's Hospital, Chattanooga
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- ak 2 plis
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT04895709Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Tennessee Oncology, PLLC, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Tennessee Oncology, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06150664Familial Investigations of Childhood Cancer Predisposition
- St. Jude Children's Research Hospital, Memphis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 17, 2026 · NCT03050268A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Jun 15, 2026 · NCT06940739Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT03947385B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
- St. Jude Children's Research Hospital, Memphis
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou May 19, 2026 · NCT04897321Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Tennessee Oncology, Chattanooga
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT05379985Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT07555210Neoadjuvant Darovasertib in Primary Uveal Melanoma
- SCRI Oncology Partners, Nashville
- Vanderbilt Eye Institute, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT07015190A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 20, 2026 · NCT06326411A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute, Nashville
- ak 1 plis
Ap rekriteFaz 2/3
Tout laj · Tout sèks · Mizajou Apr 2, 2026 · NCT06581406Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Baptist Memorial Hospital for Women, Memphis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- University of Tennessee Medical Center, Knoxville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT05549297Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
- Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT04903119A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 136, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 21, 2025 · NCT05914116Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
- St. Jude Children's Research Hospital, Memphis
Ap rekriteEtid obsèvasyon
Jiska laj 18 · Tout sèks · Mizajou Nov 10, 2025 · NCT02775643SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
- Vanderbitl-Ingram Cancer Center, Nashville
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 19, 2025 · NCT01205815A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2025 · NCT05970497A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2025 · NCT05669430Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.